Implication of protein tyrosine phosphatase SHP-1 in cancer-related signaling pathways

Yadhu Sharma1, Altaf Ahmad2, Samina Bashir1

  • 1Department of Biochemistry, Faculty of Science, Jamia Hamdard, New Delhi-110062, India.

Insights

SHP-1 (SH2 domain-containing protein tyrosine phosphatase) alterations are linked to cancer. This review analyzes SHP-1

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • SHP-1 (SH2 domain-containing protein tyrosine phosphatase) expression is altered in cancer via methylation or mutations.
  • SHP-1 negatively regulates cell cycle and inflammatory pathways crucial for oncogenesis.
  • SHP-1 plays a significant role in immune cell signaling.

Purpose of the Study:

  • To critically analyze the role of SHP-1 in cancer progression.
  • To investigate SHP-1's regulation of cell cycle and JAK/STAT pathways.
  • To explore SHP-1's potential as a prognostic marker and therapeutic target in cancer.

Main Methods:

  • Literature review and critical analysis.
  • Focus on SHP-1's involvement in cell cycle regulation.
  • Emphasis on SHP-1's role in the JAK/STAT signaling pathway.

Main Results:

  • Altered SHP-1 expression is associated with cancer development.
  • SHP-1 influences key cell cycle components.
  • SHP-1 impacts the JAK/STAT pathway, relevant to inflammation and cancer.

Conclusions:

  • SHP-1 is a critical regulator of pathways involved in cancer progression.
  • SHP-1 presents a promising target for cancer therapy.
  • Further research can establish SHP-1 as a prognostic marker for cancer.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
19.2K